
I. Introduction
Mental disorder refers to the varying degrees of disorder of cognition, emotion, behavior and will, etc. caused by disorder of brain functional activity. Mental disorder diseases have complicated pathogenesis, and are difficult to treat, with easy relapse, bringing a great burden to patients, families and society. Mental disorders are currently based on drug treatment, and the relevant drugs are roughly divided into the following five categories by indication: 1) antidepressants; 2) antipsychotic drugs; 3) sedative-hypnotic drugs; 4) anti-anxiety drugs; 5) other mental disorder drugs. This article will introduce the market situation of mental disorder field in China, market shares of enterprises, enterprise market shares in segments, and best-selling drugs in segments, etc. And 2 Chinese enterprises and 2 overseas enterprises with outstanding performance in the mental disorder field will be introduced in the future.
II. Market Situation
According to the sample hospital database, the sales of the mental disorder drug field reached RMB 4.57 billion in China in 2017, growing by 9.7% year on year; this field includes antidepressants, antipsychotic drugs, sedative-hypnotic drugs, anti-anxiety drugs, and other mental disorder drugs. As shown in the following figure, antidepressants accounted for the largest share (41%), followed by antipsychotic drugs (31%).

|
精神障碍领域药物分类占比 |
Proportions of Drugs in Mental Disorder Field in China |
|
抗抑郁药 |
Antidepressants |
|
抗精神病药 |
Antipsychotic drugs |
|
抗焦虑药 |
Anti-anxiety drugs |
|
镇静催眠药 |
Sedative-hypnotic drugs |
|
其他类 |
Others |
Fig. 1 Proportions of Drugs in Mental Disorder Field in China
We can see from the above figure that sales of antidepressants and antipsychotic drugs accounted for over 70% of drugs of the entire mental disorder field, occupying the absolute dominance. Let’s next see the data of market shares of enterprises on the Chinese market, after a basic understanding of the sales proportions of the mental disorder segments: we can see from Fig. 2 that the Chinese enterprise Hengrui occupied 14% market share, being far ahead, followed by Lundbeck, Eli Lilly and Hansoh with market share of separately 10%, 9% and 9%.











(All Rights Reserved)